Prostaglandin E1

Dicot contracts world leading medical expert within erectile dysfunction

Retrieved on: 
Wednesday, March 8, 2023
Tadalafil, Erectile dysfunction, Urology, MUSE, The New England Journal of Medicine, News, Research, Fox, Keck School of Medicine of USC, Los Angeles Times, CNN, Pelvic floor dysfunction, Premature ejaculation, University, Drug development, Male, University of Southern California, The New York Times, Pharmaceutical industry, Prostaglandin E1, Sildenafil, Medicine

UPPSALA, Sweden , March 8, 2023 /PRNewswire/ -- Dicot has entered into a consultancy agreement with medical doctor Harin Padma-Nathan, a world leading medical expert in male sexual dysfunctions.

Key Points: 
  • UPPSALA, Sweden , March 8, 2023 /PRNewswire/ -- Dicot has entered into a consultancy agreement with medical doctor Harin Padma-Nathan, a world leading medical expert in male sexual dysfunctions.
  • Dr Padma-Nathan was involved in the development of the drugs for erectile dysfunction currently on the market, e.g., as Lead Principal Investigator during the development of Viagra and Cialis.
  • The company has now entered into a consultancy agreement with Dr Harin Padma-Nathan, a world leading medical doctor within erectile dysfunction drug development.
  • LIB-01, with its unique duration of action, promises to shift the management paradigm of erectile dysfunction.

At 6.9% CAGR, Global Erectile Dysfunction Drugs Market Size & Share Will Hit US$ 5.94 Billion | Industry Trends, Demand, Growth, Value, Analysis & Forecast Report by Zion Market Research

Retrieved on: 
Wednesday, June 22, 2022
Erectile dysfunction, CAGR, Population, Therapy, Obesity, Fear, Smoking, Cardiovascular disease, Alcoholism, Dizziness, Nasal congestion, Research, Severe cognitive impairment, Man, Adoption, Projection, OPC Historical Data Access, USD, Rash, Flushing, Marketing, Investment, Diarrhea, Sale, ED, Patient, Medicine, Strategic management, Awareness, Headache, Male, Diabetes, Risk, Dietary supplement, Pharmaceutical industry, Apomorphine, Prostaglandin E1, Tadalafil

Key Industry Insights & Finding of the Erectile Dysfunction Drugs Market Reports:

Key Points: 
  • Key Industry Insights & Finding of the Erectile Dysfunction Drugs Market Reports:
    As per the analysis shared by our research analyst, the Erectile Dysfunction Drugs Market is expected to grow annually at a CAGR of around 6.9 % (2022-2028).
  • Erectile dysfunction drugs are majorly sold in developed and emerging economies; however, the percentage of their sale is less in low- and middle-income countries.
  • Furthermore, increased investments in advertisements are also likely to contribute significantly to the expansion of the global erectile dysfunction drugs market.
  • The expanding manufacture of generic erectile dysfunction pharmaceuticals, as well as the growing availability of bogus erectile dysfunction drugs, are two important challenges for the market.

At 6.9% CAGR, Global Erectile Dysfunction Drugs Market Size & Share Will Hit US$ 5.94 Billion | Industry Trends, Demand, Growth, Value, Analysis & Forecast Report by Zion Market Research

Retrieved on: 
Wednesday, June 22, 2022
Erectile dysfunction, CAGR, Population, Therapy, Obesity, Fear, Smoking, Cardiovascular disease, Alcoholism, Dizziness, Nasal congestion, Research, Severe cognitive impairment, Man, Adoption, Projection, OPC Historical Data Access, USD, Rash, Flushing, Marketing, Investment, Diarrhea, Sale, ED, Patient, Medicine, Strategic management, Awareness, Headache, Male, Diabetes, Risk, Dietary supplement, Pharmaceutical industry, Apomorphine, Prostaglandin E1, Tadalafil

Key Industry Insights & Finding of the Erectile Dysfunction Drugs Market Reports:

Key Points: 
  • Key Industry Insights & Finding of the Erectile Dysfunction Drugs Market Reports:
    As per the analysis shared by our research analyst, the Erectile Dysfunction Drugs Market is expected to grow annually at a CAGR of around 6.9 % (2022-2028).
  • Erectile dysfunction drugs are majorly sold in developed and emerging economies; however, the percentage of their sale is less in low- and middle-income countries.
  • Furthermore, increased investments in advertisements are also likely to contribute significantly to the expansion of the global erectile dysfunction drugs market.
  • The expanding manufacture of generic erectile dysfunction pharmaceuticals, as well as the growing availability of bogus erectile dysfunction drugs, are two important challenges for the market.

ADVANZ PHARMA Corp. Limited Closes Acquisition of the Rights to a Portfolio of Alprostadil Products from UCB S.A. for $83 Million

Retrieved on: 
Wednesday, April 1, 2020
Chemical compounds, Prostaglandins, Organic compounds, Chemistry, RTT, Cyclopentanes, Ketones, Prostaglandin E1, Erectile dysfunction, Prostaglandin E, Cash and cash equivalents, Deposit

The Company today paid the purchase price of $83 million1 (75 million), and a deposit for inventory of approximately $13 million, from its cash on hand.

Key Points: 
  • The Company today paid the purchase price of $83 million1 (75 million), and a deposit for inventory of approximately $13 million, from its cash on hand.
  • As of December 31, 2019, ADVANZ PHARMA's cash and cash equivalents balance was $261 million.
  • The alprostadil product portfolio consists of two established, niche, injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease.
  • Combined sales of all alprostadil brands generated approximately $33.3 million in revenue in 2019 in the territories where ADVANZ PHARMA will hold the rights.

ADVANZ PHARMA Corp. Limited Announces Definitive Agreement to Acquire The Rights To A Portfolio Of Alprostadil Products From UCB S.A. For Approximately $84 Million

Retrieved on: 
Friday, March 6, 2020
Chemical compounds, Prostaglandins, Organic compounds, Chemistry, Cyclopentanes, Ketones, Prostaglandin E1, RTT, Erectile dysfunction, Prostaglandin E, Advanz Pharma

The transaction has a purchase price of $84 million1 (75 million) and ADVANZ PHARMA intends to pay for the acquisition with cash on hand.

Key Points: 
  • The transaction has a purchase price of $84 million1 (75 million) and ADVANZ PHARMA intends to pay for the acquisition with cash on hand.
  • On closing, ADVANZ PHARMA will also pay a deposit for inventory of approximately $14 million.
  • The alprostadil product portfolio consists of two established, niche, injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease.
  • Combined sales of all alprostadil brands generated approximately $33.3 million in revenue in 2019 in the territories where ADVANZ PHARMA will hold the rights.